<DOC>
	<DOCNO>NCT01216631</DOCNO>
	<brief_summary>The aim study establish efficacy duration effect intra-articular ( IA ) infliximab vs intravenous infliximab vs current standard care ( IA steroid injection ) seronegative oligoarthritis . All patient seronegative arthritis affect less 5 joint include least one knee . 10 patient receive IA infliximab injection affect knee , 10 receive IA steroid injection affect knee 10 receive course intravenous infliximab . Patients aware group placebo-controlled study .</brief_summary>
	<brief_title>Seronegative Oligoarthritis Knee Study ( SOKS )</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inflammatory oligoarthritis ( 4 less active joint ) least one swollen knee joint least 3 month duration Rheumatoid factor antiCCP Ab negative Either arthritis onset &lt; 45 year age , arthritis onset ≥45 year age early morning stiffness &gt; 30mins raise inflammatory marker If 40 year age , clinical exclusion diagnosis gout . If 40 year old screening , prior normal examination synovial fluid affect joint exclude crystal arthropathy infection . Failure methotrexate ( inefficacy &gt; 3 month trial , intolerance contraindication ) Have capacity understand sign inform consent form . Gender : male female 18 year age . Women must either postmenopausal ( menstrual period minimum 1 year ) surgically sterilize use adequate birth control measure negative serum pregnancy test entry study . Men woman childbearing potential must use adequate birth control measure ( e.g. , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , implantable injectable contraceptive surgical sterilization ) duration study continue precaution 6 month receive last infusion . Are consider eligible accord tuberculosis ( TB ) eligibility assessment , screening , early detection reactivation rule define protocol The screening laboratory test result must meet follow criterion WBC ( white blood cell count ) : &gt; 3.5 x 109/L ANC ( absolute neutrophil count ) : &gt; 1.5 x 109/L Hemoglobin : &gt; 10g/dL Platelets : &gt; 120 x 109/L SGPT ( ALT alanine aminotransferase ) &lt; 1.5 time upper normal limit ( i.e . 60iu/L ) Have history latent active TB prior screen . An exception make subject history latent TB documentation complete appropriate treatment latent TB ( see Appendix 3 ) within 3 year prior first administration study agent . It responsibility investigator verify adequacy previous antituberculous treatment provide appropriate documentation . Have sign symptom suggestive active TB upon medical history and/or physical examination . Have recent close contact person active TB , contact , refer physician specialize TB undergo additional evaluation , warrant , receive appropriate treatment latent TB prior first administration study agent . Within 6 week prior first administration study agent , either negative QuantiFeron test result ( see Appendix 3 ) newly identify positive QuantiFeron test result screen active TB rule appropriate treatment latent TB initiate prior first administration study agent . Have chest radiograph ( posterioranterior view require , lateral view ) , take within 3 month prior first administration study agent read qualified radiologist , evidence current , active TB old , inactive TB . Grade 4 osteoarthritis ( KellgrenLawrence score ) plain radiograph knee Rheumatoid Arthritis ( define ACR criterion diagnosis RA , 1987 ) Ankylosing Spondylitis ( define modify New York Criteria ) Clinical diagnosis gout previous evidence crystal arthropathy synovial fluid aspirate Women pregnant , nursing , plan pregnancy within 6 month last infusion ( include father 's plan father child within 6 month last infusion ) . Have previous treatment biological therapy . History receive human/murine recombinant product know allergy murine product . A known allergy murine product definitely exclusion criterion Previous intramuscular , intraarticular intravenous steroid within 4 week prior baseline . Previous oral steroid dose &gt; 10mg/day prednisolone equivalent 4 week prior baseline . Documentation seropositive human immunodeficiency virus ( HIV ) . Documentation positive test hepatitis B surface antigen hepatitis C. Have history alcohol substance abuse within precede 6 month , opinion investigator , may increase risk associate study participation study agent administration , may interfere interpretation result . Have know history serious infection ( e.g. , hepatitis , pneumonia , pyelonephritis ) previous 3 month . Have opportunistic infection ( e.g. , herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month prior screen Have Bacille CalmetteGuérin ( BCG ) vaccination within 12 month screen . Are consider ineligible accord TB eligibility assessment , screening , early detection reactivation rule describe Appendix 3 . Have chest radiograph within 3 month prior first administration study agent show abnormality suggestive malignancy current active infection . Have history lymphoproliferative disease , include lymphoma sign suggestive possible lymphoproliferative disease lymphadenopathy unusual size location ( e.g. , node posterior triangle neck , infraclavicular , epitrochlear , periaortic area ) , splenomegaly . Currently know malignancy condition treat history malignancy , exception basal cell squamous cell carcinoma skin fully excise evidence recurrence . Have current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease . Are unable unwilling undergo multiple venipuncture poor tolerability lack easy access . Use investigational drug within 30 day prior screen within 5 halflives investigational agent , whichever longer . Presence transplant solid organ ( exception corneal transplant &gt; 3 month prior screen ) . Have concomitant diagnosis history congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>seronegative</keyword>
	<keyword>oligoarthritis</keyword>
	<keyword>infliximab</keyword>
	<keyword>intraarticular</keyword>
</DOC>